An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor

Gloria Ravegnini, Milena Urbini, Vittorio Simeon, Chiara Genovese, Annalisa Astolfi, Margherita Nannini, Lidia Gatto, Maristella Saponara, Manuela Ianni, Valentina Indio, Giovanni Brandi, Stefania Trino, Patrizia Hrelia, Guido Biasco, Sabrina Angelini, Maria A Pantaleo

Research output: Contribution to journalArticlepeer-review

Abstract

Imatinib represents the standard therapy for gastrointestinal stromal tumor (GIST) patients with metastatic/unresectable disease. Despite the excellent results achieved with its introduction, the majority of patients quite invariably experience disease progression. The aim of this study was to understand the contribution of germline DNA polymorphisms in discriminating between imatinib clinical response [evaluated as progression free survival (PFS)] and toxicity. In particular, a discovery cohort (34 GIST with a KIT exon 11 primary mutation, and no toxicity) was analyzed through DMET array that interrogates 1936 variants in 231 genes of the ADME process. We further confirmed the genotype of selected variants in an extended cohort of 49 patients (the original cohort and 15 new cases, all with exon 11 primary mutation), identifying 6 SNPs- ABCB4 rs1202283, ABCC2 rs2273697, ABCG1 rs1541290, CYP11B1 rs7003319, CYP7B1 rs6987861, and NQO1 rs10517-significantly associated with response to imatinib. Three SNPs, ABCB4 rs1202283, ABCC2 rs2273697, and NQO1 rs10517, which had a significant association after adjusted multivariate analysis, were included in a genetic prediction model. We confirmed that these SNPs could stratify the cohort of 49 patients according to the risk of developing progression under imatinib treatment. In conclusion, we identified a genetic signature of response to imatinib therapy in GIST patients able to stratify patients at low and high risk to progress, according to their genotype.

Original languageEnglish
JournalPharmacogenomics Journal
DOIs
Publication statusE-pub ahead of print - Sep 20 2018

Fingerprint Dive into the research topics of 'An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor'. Together they form a unique fingerprint.

Cite this